PharmaDepth

Company profile

TRAVERE THERAPEUTICS, INC.

NASDAQ:TVTXBiotechnology: Pharmaceutical Preparations

Drug pipeline (1)

AssetStageRevenueTrialsStatus
FILSPARIapproved$141.1MQ2 20269approved

Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.

Clinical trials (11)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT06431893phase3enrolling_by_invitation2024-04-302030-08-01Travere Therapeutics, Inc.A Long-term Extension Study to Assess the Long-term Safety and Efficacy of Pegtibatinase Treatment in Participants ≥5 to ≤65 Years of Age With Classical Homocystinuria (HCU) (ENSEMBLE)
NCT03762850phase3active_not_recruiting2018-12-112023-08-07Travere Therapeutics, Inc.A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy
NCT06247085phase3recruiting2023-12-282027-08-01Travere Therapeutics, Inc.A Study to Investigate Efficacy and Safety of Pegtibatinase Compared With Placebo in Participants ≥12 to ≤65 Years of Age With Classical Homocystinuria (HCU) Due to Cystathionine Beta Synthase Deficiency Receiving Standard of Care Treatment
NCT05856760phase2completed2023-05-192024-10-14Travere Therapeutics, Inc.A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN
NCT03041116phase3terminated2017-07-172019-12-30Travere Therapeutics, Inc.Efficacy and Safety Study of Fosmetpantotenate (RE-024) in PKAN Participants

FDA applications (1)

ApplicationApprovedTypeApplicantProducts
NDA 2164032023-02-17NDATRAVERE THERAPEUTICS INC